Initial Oral Antibiotics for Bone and Joint Infections in Children
Launched by RIGSHOSPITALET, DENMARK · Feb 13, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effectiveness and safety of starting treatment with oral antibiotics for children and teenagers who have uncomplicated bone and joint infections. Previous research has shown that oral antibiotics can work just as well as intravenous (IV) antibiotics, which are given through a vein, but we need to see how well oral antibiotics perform in real-world situations. The goal is to gather more information on how these medications can help young patients with bone and joint infections.
To be eligible for this study, children and adolescents aged 3 months to 17 years must have uncomplicated bone and joint infections and will be treated with initial oral antibiotics. Certain risk factors, like severe illness or rapid worsening of symptoms, will exclude some patients from participating. Those who join the trial can expect regular follow-ups to monitor their health and the effectiveness of the treatment. This study is currently recruiting participants, and it aims to improve understanding of how to best treat these infections in young patients.
Gender
ALL
Eligibility criteria
- • Children and adolescents aged 3 months to 17 years with uncomplicated bone and joint infections treated with initial oral antibiotics.
- According to Danish Nationwide Guidelines (initiated in 2024), initial oral antibiotics are recommended to patients with no risk factors for complicated disease. Risk factors include for complicated disease include:
- • 1. Severe illness or sepsis
- • 2. Rapid symptom progression
- • 3. Pronounced symptoms, including severe pain
- • 4. Pronounced soft tissue involvement
- • 5. Foreign material or post-surgical infection
- • 6. Infection with a resistent or rare pathogen, e.g., Salmonella or MRSA
- • 7. Severe comorbidity, including immunodeficiency
- • Patients who have received intravenous antibiotic therapy for less than 24 h before oral antibiotics will be included
About Rigshospitalet, Denmark
Rigshospitalet, located in Copenhagen, Denmark, is one of the leading hospitals in Scandinavia and a prominent center for clinical research and innovation. As a key academic institution affiliated with the University of Copenhagen, Rigshospitalet is dedicated to advancing healthcare through rigorous clinical trials and groundbreaking research across various medical disciplines. The hospital’s commitment to excellence is reflected in its multidisciplinary approach, collaboration with international research networks, and focus on improving patient outcomes through evidence-based practices. With state-of-the-art facilities and a team of highly qualified professionals, Rigshospitalet plays a crucial role in translating scientific discoveries into effective treatments and therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Copenhagen ø, , Denmark
Patients applied
Trial Officials
Ulrikka Nygaard, Ass Professor, PhD, MD, MPhil
Study Chair
Copenhagen University Hospital, Rigshospitalet, Denmark
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported